PL435199A1 - Kompozycja bakteriofagów specyficzna wobec bakterii z rodziny Enterobacterlaceae, zwłaszcza Escherichia coli, zastosowanie kompozycji bakteriofagów do leczenia zakażeń wywołanych przez bakterie z rodziny Enterobacterlaceae, zwłaszcza Escherichia coli oraz zastosowanie kompozycji bakteriofagów jako czynnika biokontroli - Google Patents
Kompozycja bakteriofagów specyficzna wobec bakterii z rodziny Enterobacterlaceae, zwłaszcza Escherichia coli, zastosowanie kompozycji bakteriofagów do leczenia zakażeń wywołanych przez bakterie z rodziny Enterobacterlaceae, zwłaszcza Escherichia coli oraz zastosowanie kompozycji bakteriofagów jako czynnika biokontroliInfo
- Publication number
- PL435199A1 PL435199A1 PL435199A PL43519920A PL435199A1 PL 435199 A1 PL435199 A1 PL 435199A1 PL 435199 A PL435199 A PL 435199A PL 43519920 A PL43519920 A PL 43519920A PL 435199 A1 PL435199 A1 PL 435199A1
- Authority
- PL
- Poland
- Prior art keywords
- bacteriophage composition
- escherichia coli
- enterobacterlaceae
- particular escherichia
- bacteriophage
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 241001515965 unidentified phage Species 0.000 title abstract 5
- 241000588724 Escherichia coli Species 0.000 title abstract 3
- 230000000443 biocontrol Effects 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 241000588921 Enterobacteriaceae Species 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Przedmiotem zgłoszenia jest kompozycja bakteriofagów specyficzna wobec bakterii z rodziny Enterobacteriaceae, zwłaszcza Escherichia coli zdeponowana w Polskiej Kolekcji Mikroorganizmów (PCM) pod numerem depozytowym F/00156. Zgłoszenie obejmuje też zastosowanie kompozycji bakteriofagów do wytwarzania leczniczych preparatów przeciwbakteryjnych służących do zwalczania bakterii z rodziny Enterobacteriaceae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL435199A PL240027B1 (pl) | 2020-09-03 | 2020-09-03 | Kompozycja bakteriofagów specyficzna wobec bakterii z rodziny Enterobacteriaceae, zwłaszcza Escherichia coli, zastosowanie kompozycji bakteriofagów w zwalczaniu bakterii z rodziny Enterobacteriaceae, zwłaszcza Escherichia coli oraz zastosowanie kompozycji bakteriofagów jako czynnika biokontroli |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL435199A PL240027B1 (pl) | 2020-09-03 | 2020-09-03 | Kompozycja bakteriofagów specyficzna wobec bakterii z rodziny Enterobacteriaceae, zwłaszcza Escherichia coli, zastosowanie kompozycji bakteriofagów w zwalczaniu bakterii z rodziny Enterobacteriaceae, zwłaszcza Escherichia coli oraz zastosowanie kompozycji bakteriofagów jako czynnika biokontroli |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL435199A1 true PL435199A1 (pl) | 2021-04-06 |
| PL240027B1 PL240027B1 (pl) | 2022-02-07 |
Family
ID=75297950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL435199A PL240027B1 (pl) | 2020-09-03 | 2020-09-03 | Kompozycja bakteriofagów specyficzna wobec bakterii z rodziny Enterobacteriaceae, zwłaszcza Escherichia coli, zastosowanie kompozycji bakteriofagów w zwalczaniu bakterii z rodziny Enterobacteriaceae, zwłaszcza Escherichia coli oraz zastosowanie kompozycji bakteriofagów jako czynnika biokontroli |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL240027B1 (pl) |
-
2020
- 2020-09-03 PL PL435199A patent/PL240027B1/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL240027B1 (pl) | 2022-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gonzalez-Barca et al. | Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution | |
| Aiyegoro et al. | In vitro antibacterial activities of crude extracts of the leaves of Helichrysum longifolium in combination with selected antibiotics | |
| Husain et al. | Analysis of infection in a burn ward | |
| Magnet et al. | Isolation and identification of different bacteria from different types of burn wound infections and study their antimicrobial sensitivity pattern | |
| Sofy et al. | Evaluation of Antibacterial and Antibiofilm Activity of New Antimicrobials as an Urgent Need to Counteract Stubborn Multidrug-resistant Bacteria. | |
| US20210361738A1 (en) | Bacteriophage-derived recombinant protein having antimicrobial activity against pathogenic gram-negative bacteria | |
| Maple et al. | Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus | |
| CN108042614A (zh) | 丁香挥发油用于杀菌和/或抑菌、抗耐药菌的应用 | |
| EA202190207A1 (ru) | Антимикробная композиция и ее применение | |
| CN116139143B (zh) | 天然药物在制备抗革兰氏阳性菌药物中的应用 | |
| Choi et al. | Clinical significance of Staphylococcus saprophyticus identified on blood culture in a tertiary care hospital | |
| WO2024030896A3 (en) | Bacteriophage compositions and methods for treatment of bacterial infections | |
| Karim et al. | Bacterial isolates in neutropenic febrile patients | |
| CN110279679A (zh) | 柠檬醛在抑制多重耐药阴沟肠杆菌生长中的应用 | |
| Lanzafame et al. | In vitro activity of levofloxacin against recent Gram-negative nosocomial pathogens | |
| Takahata et al. | In-vitro and in-vivo activities of T-3262, a new pyridone carboxylic acid | |
| Selwyn et al. | In vitro and in vivo studies on antibiotics from skin micrococcaceae | |
| CN110974838B (zh) | 金化合物在制备抗菌剂中的应用 | |
| Gibson et al. | Trends in bacterial infections in febrile neutropenic patients: 1986–1992 | |
| Kahaleq et al. | Antibacterial activity of Fenugreek essential oil against Pseudomonas aeroginosa: In vitro and in vivo Studies | |
| Al-naimi et al. | Research article recurrent urinary tract infections in iraqi leukemic patients | |
| Muhammad et al. | Prevalence of pathogenic bacteria isolated from surgical site and wound infection among patients admitted in some selected hospitals in Sokoto metropolis, Nigeria | |
| Wali et al. | Fosfomycin Versus Nitrofurantoin Efficacy Against Multi-Drug Resistant Gram Negative Urinary Pathogens. | |
| Özbil et al. | Antibacterial Potency of Ibuprofen and Its Interaction with Ciprofloxacin Against Gram Positive and Gram Negative Bacteria | |
| JP2022545652A5 (pl) |